Screener
Nuvectis Pharma, Inc. NVCT Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31 / 2026 | Three Months Ended March 31 / 2025 |
|---|---|---|
| Research and development | $4,106 | $3,680 |
| General and administrative | 2,154 | 1,888 |
| OPERATING LOSS | (6,260) | (5,568) |
| Finance income | 210 | 236 |
| NET LOSS | $(6,050) | $(5,332) |
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $(6,050) | $(5,332) |
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 | $(0.26) | $(0.27) |
| Basic and diluted weighted average number of common shares outstanding | 23,414,475 | 19,937,507 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s net income?
- Nuvectis Pharma, Inc. (NVCT) reported net income of -$6.05M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s net income changed year-over-year?
- Nuvectis Pharma, Inc.'s net income decreased by 13.5% year-over-year, from -$5.33M to -$6.05M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s net income?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s net income has grown at a 19.7% compound annual growth rate (CAGR), from -$12.89M to -$26.44M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Nuvectis Pharma, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude